"Tocor II"

Comprises papers relating to Marc Feldmann's role as a board member on the Tocor II Board of Directors. Tocor II (formed in 1991) was set up by Centocor as a financing vehicle to engage in research development and preliminary clinical studies in the field of small peptide molecule based pharmaceutical products for the treatment of human diseases.

The item contains board of directors meeting correspondence; correspondence relating to TNF research data; monthly, quarterly and annual reports; peptide research development plans, program reports, presentation slides, patent papers and data; Tocor II stock prospectus; papers relating to research and development agreement with Centocor; special committee meeting minutes and some papers relating to Kennedy Institute involvement with Centocor.

1992-1997

1 file (in 4 parts)

This item requires facilitated access. Email library@wellcomecollection.org to request an appointment. This item is also restricted. You will need to complete a Restricted Access form agreeing to anonymise personal data before you will be allowed to view this item. Please see our Access Policy for more details. Restricted until 1 January 2035.